{"genes":["CTLA-4 antibody","BRAF","BRAF","BRAF"],"publicationTypes":["Journal Article"],"abstract":"Recently, a CTLA-4 antibody and BRAF inhibitors showed survival benefits in advance melanoma treatment. The documentation of immune infiltrates in melanomas early during BRAF inhibitor therapy provides a scientific rationale for combination therapy with both treatments with possible synergistic benefits. This commentary reviews immune responses induced by BRAF inhibitors.","title":"Combined targeted therapy and immunotherapy in the treatment of advanced melanoma.","pubmedId":"23189245"}